ArticleScientific reports2017

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.

Hai-Yuan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.